Dimethyltryptamine/harmine
Pharmaceutical compound
From Wikipedia, the free encyclopedia
Dimethyltryptamine/harmine (developmental code name RE01 or RE-01) is a combination of dimethyltryptamine (DMT), a tryptamine serotonin receptor agonist and serotonergic psychedelic, and harmine, a β-carboline reversible inhibitor of monoamine oxidase A (RIMA), which is under development for the treatment of mood disorders.[1][2][3]
administrationUnspecified[1]
 | |
 | |
| Combination of | |
|---|---|
| Dimethyltryptamine | Serotonergic psychedelic; Serotonin receptor agonist |
| Harmine | Reversible inhibitor of monoamine oxidase A |
| Clinical data | |
| Other names | DMT/harmine; Harmine/dimethyltryptamine; Harmine/DMT; Dimethyltryptamine/telepathine; DMT/telepathine; Telepathine/dimethyltryptamine; telepathine/DMT; RE01 |
| Routes of administration | Unspecified[1] |
It is a form of pharmahuasca (pharmaceutical ayahuasca), in which DMT is combined with a synthetically produced monoamine oxidase inhibitor (MAOI) as opposed to a plant-derived form such as Banisteriopsis caapi as in ayahuasca.[4] Harmine, acting as a RIMA, inhibits the metabolism of DMT, in turn greatly potentiating DMT and allowing it to become orally active.[5][6][7]
The combination is being developed by Reconnect Labs.[1][2][3] As of August 2023, it is in phase 1 clinical trials.[1][2][3]